Avita Therapeutics (ASX:AVH) saw its stock price surge 5.26% in Tuesday's trading session following the release of positive data for its Recell system. The company announced that researchers presented compelling evidence at the annual meeting of the British Burn Association, demonstrating significant benefits for burn patients treated with the Recell system.

The study, which represents the largest real-world analysis of Recell to date, examined registry data from over 6,300 patients treated between 2019 and 2024. For patients with burns covering less than 30% of their total body surface area, treatment with Recell Spray-On Skin Cells alone resulted in a remarkable 6.2-day (or 36%) reduction in hospital stay compared to those treated with traditional split-thickness autografts. This reduction in hospital stays translated to impressive cost savings of approximately AU$300 million over the five-year study period.

These findings underscore the potential of Avita's Recell system to revolutionize burn treatment, offering substantial benefits to both patients and healthcare systems. The positive data is likely driving investor optimism, as it suggests strong growth potential for Avita Therapeutics in the burn treatment market. As the company continues to demonstrate the efficacy and cost-effectiveness of its innovative technology, it may see increased adoption in hospitals and burn centers worldwide, potentially leading to significant revenue growth in the coming years.